HUTCHMED (NASDAQ:HCM) Hits New 52-Week Low – What’s Next?

Shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $10.63 and last traded at $10.7790, with a volume of 7730 shares traded. The stock had previously closed at $10.85.

Analyst Ratings Changes

HCM has been the subject of a number of research analyst reports. Morgan Stanley set a $13.60 target price on HUTCHMED in a research note on Thursday, May 28th. Weiss Ratings lowered HUTCHMED from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 1st. Wall Street Zen lowered HUTCHMED from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Bank of America reduced their target price on HUTCHMED from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, March 10th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, HUTCHMED presently has a consensus rating of “Hold” and a consensus target price of $16.80.

HUTCHMED Stock Performance

The company has a debt-to-equity ratio of 0.05, a current ratio of 4.96 and a quick ratio of 4.83. The firm’s fifty day simple moving average is $13.28 and its 200 day simple moving average is $13.98.

Institutional Investors Weigh In On HUTCHMED

Several hedge funds have recently added to or reduced their stakes in HCM. Amundi increased its holdings in HUTCHMED by 4.0% in the first quarter. Amundi now owns 232,246 shares of the company’s stock valued at $3,474,000 after buying an additional 8,916 shares in the last quarter. Janney Montgomery Scott LLC acquired a new position in shares of HUTCHMED in the first quarter worth about $365,000. State Street Corp boosted its stake in shares of HUTCHMED by 1.2% during the 4th quarter. State Street Corp now owns 321,305 shares of the company’s stock worth $4,283,000 after acquiring an additional 3,801 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of HUTCHMED by 3.0% during the 4th quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock worth $1,798,000 after acquiring an additional 3,900 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of HUTCHMED by 157.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 55,969 shares of the company’s stock worth $746,000 after acquiring an additional 34,248 shares in the last quarter. 8.82% of the stock is owned by hedge funds and other institutional investors.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.